In acute leukemia (AML), KMT2D has been demonstrated to regulate ribosomal biogenesis by modulating the mTOR signaling pathway, thereby influencing tumorigenesis and progression [25]. This evidence concerns the gene MTOR and acute myeloid leukemia.